Trial Profile
Vinorelbine in Mesothelioma (Vim): a Randomised Phase II Trial of Oral Vinorelbine as Second-Line Therapy for Patients with Malignant Pleural Mesothelioma (Mpm) Expressing Brca1
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2012
Price :
$35
*
At a glance
- Drugs Vinorelbine (Primary)
- Indications Malignant-mesothelioma
- Focus Pharmacogenomic; Therapeutic Use
- Acronyms VIM
- 06 Nov 2012 New trial record